Dr. Reddys Laboratories Ltd 2017 AR2
The report outlines Dr. Reddy's Laboratories' performance and initiatives for the fiscal year 2016-17. During this period, the company faced a challenging year with consolidated revenues declining by 9% to ₹140.8 billion, primarily due to USFDA warning letters affecting key plants and increased competition in the US market. Despite these challenges, the company launched 93 new products globally and expanded its European footprint. On the sustainability front, the company achieved a 76% co-processing rate for its hazardous waste and implemented 153 energy conservation projects, reducing greenhouse gas emissions by 20,927 tonnes of CO2e.
Company: Dr. Reddys Laboratories Ltd
Sector: Health Care
Country: India
Year: 2017
Type: AR2
Pages: 264
Back to company
Dr. Reddys Laboratories Ltd
Annual Report
The report outlines Dr. Reddy's Laboratories' performance and initiatives for the fiscal year 2016-17. During this period, the company faced a challenging year with consolidated revenues declining by 9% to ₹140.8 billion, primarily due to USFDA warning letters affecting key plants and increased competition in the US market. Despite these challenges, the company launched 93 new products globally and expanded its European footprint. On the sustainability front, the company achieved a 76% co-processing rate for its hazardous waste and implemented 153 energy conservation projects, reducing greenhouse gas emissions by 20,927 tonnes of CO2e.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2017
Reporting Period
Apr 1, 2016 - Mar 31, 2017
Fiscal Year
2017
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees